Mobile

A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of reduction in International Prostate Symptom Score (IPSS)...

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-004338-26

A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of reduction in International Prostate Symptom Score (IPSS), in patients with lower urinary tract symptoms (LUTS) secondary to locally advanced prostate cancer

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that LUTS relief with degarelix is non-inferior to goserelin plus bicalutamide, based on a reduction in IPSS at 12 weeks as compared to baseline.

Critère d'inclusion

  • Prostate cancer

Liens